Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ertapenem - Merck & Co

Drug Profile

Ertapenem - Merck & Co

Alternative Names: Ertapenem sodium; Invanz; L 749345; MK 0826; MK 826; ZD 4433

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Merck & Co
  • Class Amides; Anti-infectives; Antibacterials; Benzoic acids; Carbapenems; Pyrrolidines; Small molecules; Sulfides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Community-acquired pneumonia; Intra-abdominal infections; Obstetric and gynaecological infections; Skin and soft tissue infections; Urinary tract infections

Most Recent Events

  • 27 Jul 2018 First generic equivalent available in USA
  • 24 Jun 2018 Biomarkers information updated
  • 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote ertapenem in South Korea for Bacterial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top